All In MedTech

Device Trial Radar · NCT00277095

ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males

Clinical Investigation of the ProACT Adjustable Continence Therapy for Treatment of Post-Prostatectomy Stress Urinary Incontinence

Last checked: Nov 20, 2026Latest source record: May 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

123

Actual

Start

Aug 2005

Primary completion

Feb 2009

Study completion Dec 2017

Sponsor

Lead sponsor
UromedicaNot on our public-company list
Sponsor type
Industry
First posted
Jan 13, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 109 male patients. The ProACT device is designed to treat men who have stress urinary incontinence arising from intrinsic sphincter deficiency following an operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence. The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether patients demonstrate at least a 50% reduction in pad weight at 18 months follow-up compared to the pad weight results at baseline.

Conditions

  • Urinary Incontinence

Interventions

  • ProACT (Adjustable Continence Therapy)Device

    Implantable device to reduce urinary stress incontinence

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.Time frame: 18 month follow-up

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

  • Kaiser Permanente-Los Angeles

    Los Angeles, California

  • The Pelvic Clinic

    Pembroke Pines, Florida

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.